NVAX | tickerfilter.com

Fundamental analysis

41%

Profitability 25%

Dept financing 50%

Liquidity 45%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.11%

1 Month

19.18%

3 Months

59.79%

6 Months

29.11%

1 Year

34.97%

2 Year

108.38%

Key data

Stock price

$10.69

P/E Ratio

2.48

DAY RANGE

$10.44 - $10.82

EPS

$2.72

52 WEEK RANGE

$5.01 - $11.97

52 WEEK CHANGE

$31.98

MARKET CAP

1.092 B

YIELD

N/A

SHARES OUTSTANDING

162.936 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

1.02

PUBLIC FLOAT

AVERAGE 10 VOLUME

$4,543,406

AVERAGE 30 VOLUME

$5,122,501

Company detail

CEO: Stanley C. Erck
Region: US
Website: novavax.com
Employees: 1,990
IPO year: 1995

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

NVAX - NOVAVAX INC